Prognostic markers for acute heart failure

Expert Opinion on Medical Diagnostics

Volumn 7, Issue 4, 2013, Pages 379-392

  Pascual Figal, Domingo A ^a   Caballero, Luis ^a   Sanchez Mas, Jesús ^a   Lax, Antonio ^a  

^a UNIVERSITY OF MURCIA   (Spain)

Author keywords

Acute heart failure; Biomarkers; Prognosis; Risk

Indexed keywords

ADRENOMEDULLIN; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CARDIAC TROPONIN; COPEPTIN; CREATININE; CYSTATIN C; GALECTIN 3; KIDNEY INJURY MOLECULE 1; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; SOLUBLE ST2; TROPONIN; UNCLASSIFIED DRUG;

ACUTE HEART FAILURE; CARDIORENAL SYNDROME; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CLINICAL PRACTICE; CREATININE BLOOD LEVEL; DISEASE ASSOCIATION; EMERGENCY WARD; GLOMERULUS FILTRATION RATE; HEALTH CARE COST; HEART DEATH; HEART PERFUSION; HOSPITAL ADMISSION; HOSPITAL READMISSION; HUMAN; MULTICENTER STUDY (TOPIC); PREDICTIVE VALUE; RECURRENT DISEASE; REVIEW; RISK ASSESSMENT; STRATIFICATION; SYSTEMATIC REVIEW; UREA NITROGEN BLOOD LEVEL; ACUTE DISEASE; HEART FAILURE; METABOLISM; PROGNOSIS; RISK FACTOR;

ACUTE DISEASE; BIOLOGICAL MARKERS; HEART FAILURE; HUMANS; PROGNOSIS; RISK FACTORS;

EID: 84879661989     PISSN: 17530059     EISSN: 17530067     Source Type: Journal    
DOI: 10.1517/17530059.2013.814638     Document Type: Review

References (104)

1. Gheorghiade M, Zannad F, Sopko G, et al. Acute heart failure syndromes: Current state and framework for future research. Circulation 2005 ;112(25):3958-68 (Pubitemid 43739494)
2. McMurray JJ, Adamopoulos S, Anker SD, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012 ;33(14):1787-847
3. Cleland JG, Swedberg K, Cohen-Solal A, et al. The Euro Heart Failure Survey of the EUROHEART survey programme. A survey on the quality of care among patients with heart failure in Europe. The Study Group on Diagnosis of the Working Group on Heart Failure of the European Society of Cardiology. The Medicines Evaluation Group Centre for Health Economics University of York. Eur J Heart Fail 2000 ;2(2):123-32 (Pubitemid 30407551)
4. Jessup M, Abraham WT, Casey DE, et al. 2009 focused update: ACCF/ AHA guidelines for the diagnosis and management of heart failure in adults: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: Developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009 ;119(14):1977-2016
5. Rudiger A, Harjola VP, Muller A, et al. Acute heart failure: Clinical presentation, one-year mortality and prognostic factors. Eur J Heart Fail 2005 ;7(4):662-70 (Pubitemid 40733001)
6. Cleland JG, Swedberg K, Follath F, et al. The EuroHeart Failure survey programme-A survey on the quality of care among patients with heart failure in Europe. Part 1: Patient characteristics and diagnosis. Eur Heart J 2003 ;24(5):442-63 (Pubitemid 36286187)
7. Zannad F, Mebazaa A, Juilliere Y, et al. Clinical profile, contemporary management and one-year mortality in patients with severe acute heart failure syndromes: The EFICA study. Eur J Heart Fail 2006 ;8(7):697-705 (Pubitemid 44754746)
8. Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics-2013 update: A report from the American Heart Association. Circulation 2013;127(1):e6-e245
9. Fang J, Mensah GA, Croft JB, Keenan NL. Heart failure-related hospitalization in the U.S., 1979 to 2004. J Am Coll Cardiol 2008 ;52(6):428-34 (Pubitemid 352040814)
10. Nieminen MS, Brutsaert D, Dickstein K, et al. EuroHeart Failure Survey II (EHFS II): A survey on hospitalized acute heart failure patients: Description of population. Eur Heart J 2006 ;27(22):2725-36 (Pubitemid 44729876)
11. Jhund PS, MacIntyre K, Simpson CR, et al. Long-Term trends in first hospitalization for heart failure and subsequent survival between 1986 and 2003: A population study of 5.1 million people. Circulation 2009 ;119(4):515-23
12. Lloyd-Jones D, Adams R, Carnethon M, et al. Heart disease and stroke statistics-2009 update: A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2009 ;119(3):480-6
13. Aranda JM Jr, Johnson JW, Conti JB. Current trends in heart failure readmission rates: Analysis of medicare data. Clin Cardiol 2009 ;32(1):47-52
14. Fonarow GC, Heywood JT, Heidenreich PA, et al. Temporal trends in clinical characteristics, treatments, and outcomes for heart failure hospitalizations, 2002 to 2004: Findings from Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J 2007 ;153(6):1021-8 (Pubitemid 46809844)
15. Solomon SD, Dobson J, Pocock S, et al. Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. Circulation 2007 ;116(13):1482-7 (Pubitemid 47480639)
16. Collins SP, Lindsell CJ, Naftilan AJ, et al. Low-risk acute heart failure patients: External validation of the Society of Chest Pain Center's recommendations. Crit Pathw Cardiol 2009 ;8(3):99-103
17. Hsieh M, Auble TE, Yealy DM. Validation of the acute heart failure index. Ann Emerg Med 2008 ;51(1):37-44 (Pubitemid 350309463)
18. O'Connor CM, Stough WG, Gallup DS, et al. Demographics, clinical characteristics, and outcomes of patients hospitalized for decompensated heart failure: Observations from the IMPACT-HF registry. J Card Fail 2005 ;11(3):200-5 (Pubitemid 40462423)
19. Adams KF Jr, Fonarow GC, Emerman CL, et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: Rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J 2005 ;149(2):209-16 (Pubitemid 40348525)
20. Gheorghiade M, Gattis WA, O'Connor CM, et al. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: A randomized controlled trial. JAMA 2004 ;291(16):1963-71 (Pubitemid 38544277)
21. Lucas C, Johnson W, Hamilton MA, et al. Freedom from congestion predicts good survival despite previous class IV symptoms of heart failure. Am Heart J 2000 ;140(6):840-7
22. Fonarow GC, Adams KF Jr, Abraham WT, et al. Risk stratification for in-hospital mortality in acutely decompensated heart failure: Classification and regression tree analysis. JAMA 2005 ;293(5):572-80 (Pubitemid 40171239)
23. O'Connor CM, Mentz RJ, Cotter G, et al. The PROTECT in-hospital risk model: 7-Day outcome in patients hospitalized with acute heart failure and renal dysfunction. Eur J Heart Fail 2012 ;14(6):605-12
24. Tomcikova D, Felsoci M, Spinar J, et al. Risk of in-hospital mortality identified according to the typology of patients with acute heart failure: Classification tree analysis on data from the acute heart failure database-main registry. J Crit Care 2013 ;28(3):250-8
25. Gheorghiade M, Abraham WT, Albert NM, et al. Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure. JAMA 2006 ;296(18):2217-26 (Pubitemid 44708052)
26. Ambrosy AP, Vaduganathan M, Mentz RJ, et al. Clinical profile and prognostic value of low systolic blood pressure in patients hospitalized for heart failure with reduced ejection fraction: Insights from the Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST) trial. Am Heart J 2013 ;165(2):216-25
27. Lee DS, Ghosh N, Floras JS, et al. Association of blood pressure at hospital discharge with mortality in patients diagnosed with heart failure. Circ Heart Fail 2009 ;2(6):616-23
28. Nohria A, Tsang SW, Fang JC, et al. Clinical assessment identifies hemodynamic profiles that predict outcomes in patients admitted with heart failure. J Am Coll Cardiol 2003 ;41(10):1797-804 (Pubitemid 36584255)
29. Kociol RD, McNulty SE, Hernandez AF, et al. Markers of decongestion, dyspnea relief, and clinical outcomes among patients hospitalized with acute heart failure. Circ Heart Fail 2013 ;6(2):240-5
30. Heywood JT, Fonarow GC, Costanzo MR, et al. High prevalence of renal dysfunction and its impact on outcome in 118,465 patients hospitalized with acute decompensated heart failure: A report from the ADHERE database. J Card Fail 2007 ;13(6):422-30 (Pubitemid 47179911)
31. Carubelli V, Metra M, Lombardi C, et al. Renal dysfunction in acute heart failure: Epidemiology, mechanisms and assessment. Heart Fail Rev 2012 ;17(2):271-82
32. Butler J, Chirovsky D, Phatak H, et al. Renal function, health outcomes, and resource utilization in acute heart failure: A systematic review. Circ Heart Fail 2010 ;3(6):726-45
33. Damman K, Navis G, Voors AA, et al. Worsening renal function and prognosis in heart failure: Systematic review and meta-Analysis. J Card Fail 2007 ;13(8):599-608 (Pubitemid 47513536)
34. Van Kimmenade RR, Januzzi JL Jr, Baggish AL, et al. Amino-Terminal pro-brain natriuretic peptide, renal function, and outcomes in acute heart failure: Redefining the cardiorenal interaction? J Am Coll Cardiol 2006 ;48(8):1621-7 (Pubitemid 44528169)
35. Aronson D, Mittleman MA, Burger AJ. Elevated blood urea nitrogen level as a predictor of mortality in patients admitted for decompensated heart failure. Am J Med 2004 ;116(7):466-73 (Pubitemid 38388616)
36. Filippatos G, Rossi J, Lloyd-Jones DM, et al. Prognostic value of blood urea nitrogen in patients hospitalized with worsening heart failure: Insights from the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Chronic Heart Failure (ACTIV in CHF) study. J Card Fail 2007 ;13(5):360-4 (Pubitemid 46977793)
37. Lassus J, Harjola VP, Sund R, et al. Prognostic value of cystatin C in acute heart failure in relation to other markers of renal function and NT-proBNP. Eur Heart J 2007 ;28(15):1841-7 (Pubitemid 47236639)
38. Campbell CY, Clarke W, Park H, et al. Usefulness of cystatin C and prognosis following admission for acute heart failure. Am J Cardiol 2009 ;104(3):389-92
39. Naruse H, Ishii J, Kawai T, et al. Cystatin C in acute heart failure without advanced renal impairment. Am J Med 2009 ;122(6):566-73
40. Manzano-Fernandez S, Boronat-Garcia M, Baladejo-Oton MD, et al. Complementary prognostic value of cystatin C, N-Terminal pro-B-Type natriuretic peptide and cardiac troponin T in patients with acute heart failure. Am J Cardiol 2009 ;103(12):1753-9
41. Manzano-Fernandez S, Januzzi JL Jr, Boronat-Garcia M, et al. Beta-Trace protein and cystatin C as predictors of long-Term outcomes in patients with acute heart failure. J Am Coll Cardiol 2011 ;57(7):849-58
42. Schmidt-Ott KM, Mori K, Li JY, et al. Dual action of neutrophil gelatinase-Associated lipocalin. J Am Soc Nephrol 2007 ;18(2):407-13 (Pubitemid 46193306)
43. Aghel A, Shrestha K, Mullens W, et al. Serum neutrophil gelatinase-Associated lipocalin (NGAL) in predicting worsening renal function in acute decompensated heart failure. J Card Fail 2010 ;16(1):49-54
44. Alvelos M, Lourenco P, Dias C, et al. Prognostic value of neutrophil gelatinase-Associated lipocalin in acute heart failure. Int J Cardiol 2013 ;165(1):51-5
45. Maisel AS, Mueller C, Fitzgerald R, et al. Prognostic utility of plasma neutrophil gelatinase-Associated lipocalin in patients with acute heart failure: The NGAL EvaLuation Along with B-Type NaTriuretic Peptide in acutely decompensated heart failure (GALLANT) trial. Eur J Heart Fail 2011 ;13(8):846-51
46. Jungbauer CG, Birner C, Jung B, et al. Kidney injury molecule-1 and N-Acetylbeta-D-glucosaminidase in chronic heart failure: Possible biomarkers of cardiorenal syndrome. Eur J Heart Fail 2011 ;13(10):1104-10
47. Fonarow GC, Peacock WF, Phillips CO, et al. Admission B-Type natriuretic peptide levels and in-hospital mortality in acute decompensated heart failure. J Am Coll Cardiol 2007 ;49(19):1943-50 (Pubitemid 46694287)
48. Januzzi JL, Van Kimmenade R, Lainchbury J, et al. NT-proBNP testing for diagnosis and short-Term prognosis in acute destabilized heart failure: An international pooled analysis of 1256 patients: The International Collaborative of NT-proBNP Study. Eur Heart J 2006 ;27(3):330-7 (Pubitemid 43100029)
49. Januzzi JL Jr, Camargo CA, Anwaruddin S, et al. The N-Terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am J Cardiol 2005 ;95(8):948-54 (Pubitemid 40487743)
50. Siebert U, Januzzi JL Jr, Beinfeld MT, et al. Cost-effectiveness of using N-Terminal pro-brain natriuretic peptide to guide the diagnostic assessment and management of dyspneic patients in the emergency department. Am J Cardiol 2006 ;98(6):800-5 (Pubitemid 44301027)
51. Moe GW, Howlett J, Januzzi JL, Zowall H. N-Terminal pro-B-Type natriuretic peptide testing improves the management of patients with suspected acute heart failure: Primary results of the Canadian prospective randomized multicenter IMPROVE-CHF study. Circulation 2007 ;115(24):3103-10 (Pubitemid 46956499)
52. Maisel AS, Krishnaswamy P, Nowak RM, et al. Rapid measurement of B-Type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002 ;347(3):161-7 (Pubitemid 34764819)
53. Cheng V, Kazanagra R, Garcia A, et al. A rapid bedside test for B-Type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: A pilot study. J Am Coll Cardiol 2001 ;37(2):386-91
54. Valle R, Aspromonte N, Milani L, et al. Optimizing fluid management in patients with acute decompensated heart failure (ADHF): The emerging role of combined measurement of body hydration status and brain natriuretic peptide (BNP) levels. Heart Fail Rev 2011 ;16(6):519-29
55. Bettencourt P, Januzzi JL Jr. Amino-Terminal pro-B-Type natriuretic peptide testing for inpatient monitoring and treatment guidance of acute destabilized heart failure. Am J Cardiol 2008 ;101(3A):67-71
56. Anand IS, Fisher LD, Chiang YT, et al. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation 2003 ;107(9):1278-83 (Pubitemid 36314411)
57. Maisel AS, Choudhary R. Biomarkers in acute heart failure-state of the art. Nat Rev Cardiol 2012 ;9(8):478-90
58. Rehman SU, Januzzi JL Jr. Natriuretic peptide testing in clinical medicine. Cardiol Rev 2008 ;16(5):240-9
59. Gegenhuber A, Struck J, Dieplinger B, et al. Comparative evaluation of B-Type natriuretic peptide, mid-regional pro-A-Type natriuretic peptide, mid-regional pro-Adrenomedullin, and copeptin to predict 1-year mortality in patients with acute destabilized heart failure. J Card Fail 2007 ;13(1):42-9 (Pubitemid 46343794)
60. Potocki M, Breidthardt T, Reichlin T, et al. Midregional pro-Adrenomedullin in addition to b-Type natriuretic peptides in the risk stratification of patients with acute dyspnea: An observational study. Crit Care 2009;13(4):R122
61. Maisel A, Mueller C, Nowak RM, et al. Midregion prohormone adrenomedullin and prognosis in patients presenting with acute dyspnea: Results from the BACH (Biomarkers in Acute Heart Failure) trial. J Am Coll Cardiol 2011 ;58(10):1057-67
62. Maisel A, Xue Y, Shah K, et al. Increased 90-Day mortality in patients with acute heart failure with elevated copeptin: Secondary results from the Biomarkers in Acute Heart Failure (BACH) study. Circ Heart Fail 2011 ;4(5):613-20
63. Stoiser B, Mortl D, Hulsmann M, et al. Copeptin, a fragment of the vasopressin precursor, as a novel predictor of outcome in heart failure. Eur J Clin Invest 2006 ;36(11):771-8 (Pubitemid 44569965)
64. Peacock WF, De MT, Fonarow GC, et al. Cardiac troponin and outcome in acute heart failure. N Engl J Med 2008 ;358(20):2117-26 (Pubitemid 351679598)
65. Perna ER, Macin SM, Cimbaro Canella JP, et al. Minor myocardial damage detected by troponin T is a powerful predictor of long-Term prognosis in patients with acute decompensated heart failure. Int J Cardiol 2005 ;99(2):253-61 (Pubitemid 40320798)
66. You JJ, Austin PC, Alter DA, et al. Relation between cardiac troponin I and mortality in acute decompensated heart failure. Am Heart J 2007 ;153(4):462-70 (Pubitemid 46440690)
67. Sakhuja R, Green S, Oestreicher EM, et al. Amino-Terminal pro-brain natriuretic peptide, brain natriuretic peptide, and troponin T for prediction of mortality in acute heart failure. Clin Chem 2007 ;53(3):412-20 (Pubitemid 46447937)
68. Pascual-Figal DA, Casas T, Ordonez-Llanos J, et al. Highly sensitive troponin T for risk stratification of acutely destabilized heart failure. Am Heart J 2012 ;163(6):1002-10
69. Arenja N, Reichlin T, Drexler B, et al. Sensitive cardiac troponin in the diagnosis and risk stratification of acute heart failure. J Intern Med 2012 ;271(6):598-607
70. Metra M, Nodari S, Parrinello G, et al. The role of plasma biomarkers in acute heart failure. Serial changes and independent prognostic value of NT-proBNP and cardiac troponin-T. Eur J Heart Fail 2007 ;9(8):776-86 (Pubitemid 47212835)
71. Del Carlo CH, Pereira-Barretto AC, Cassaro-Strunz C, et al. Serial measure of cardiac troponin T levels for prediction of clinical events in decompensated heart failure. J Card Fail 2004 ;10(1):43-8 (Pubitemid 38880891)
72. Metra M, Bettari L, Pagani F, et al. Troponin T levels in patients with acute heart failure: Clinical and prognostic significance of their detection and release during hospitalisation. Clin Res Cardiol 2012 ;101(8):663-72
73. O'Connor CM, Fiuzat M, Lombardi C, et al. Impact of serial troponin release on outcomes in patients with acute heart failure: Analysis from the PROTECT pilot study. Circ Heart Fail 2011 ;4(6):724-32
74. Perna ER, Macin SM, Cimbaro Canella JP, et al. Importance of early combined N-Terminal pro-brain natriuretic peptide and cardiac troponin T measurements for long-Term risk stratification of patients with decompensated heart failure. J Heart Lung Transplant 2006 ;25(10):1230-40 (Pubitemid 44528293)
75. Xue Y, Clopton P, Peacock WF, Maisel AS. Serial changes in high-sensitive troponin I predict outcome in patients with decompensated heart failure. Eur J Heart Fail 2011 ;13(1):37-42
76. Perna ER, Aspromonte N, Cimbaro Canella JP, et al. Minor myocardial damage is a prevalent condition in patients with acute heart failure syndromes and preserved systolic function with long-Term prognostic implications. A report from the CIAST-HF (Collaborative Italo-Argentinean Study on Cardiac Troponin T in Heart Failure) study. J Card Fail 2012 ;18(11):822-30
77. Kakkar R, Lee RT. The IL-33/ ST2 pathway: Therapeutic target and novel biomarker. Nat Rev Drug Discov 2008 ;7(10):827-40
78. Januzzi JL Jr, Peacock WF, Maisel AS, et al. Measurement of the interleukin family member ST2 in patients with acute dyspnea: Results from the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) study. J Am Coll Cardiol 2007 ;50(7):607-13 (Pubitemid 47199007)
79. Rehman SU, Mueller T, Januzzi JL Jr. Characteristics of the novel interleukin family biomarker ST2 in patients with acute heart failure. J Am Coll Cardiol 2008 ;52(18):1458-65
80. Pascual-Figal DA, Manzano-Fernandez S, Boronat M, et al. Soluble ST2, high-sensitivity troponin T-And N-Terminal pro-B-Type natriuretic peptide: Complementary role for risk stratification in acutely decompensated heart failure. Eur J Heart Fail 2011 ;13(7):718-25
81. Manzano-Fernandez S, Mueller T, Pascual-Figal D, et al. Usefulness of soluble concentrations of interleukin family member ST2 as predictor of mortality in patients with acutely decompensated heart failure relative to left ventricular ejection fraction. Am J Cardiol 2011 ;107(2):259-67
82. Shah RV, Chen-Tournoux AA, Picard MH, et al. Serum levels of the interleukin-1 receptor family member ST2, cardiac structure and function, and long-Term mortality in patients with acute dyspnea. Circ Heart Fail 2009 ;2(4):311-19
83. Van Kimmenade RR, Januzzi JL Jr, Ellinor PT, et al. Utility of amino-Terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. J Am Coll Cardiol 2006 ;48(6):1217-24 (Pubitemid 44345127)
84. Shah RV, Chen-Tournoux AA, Picard MH, et al. Galectin-3, cardiac structure and function, and long-Term mortality in patients with acutely decompensated heart failure. Eur J Heart Fail 2010 ;12(8):826-32
85. Lassus J, Gayat E, Mueller C, et al. Incremental value of biomarkers to clinical variables for mortality prediction in acutely decompensated heart failure: The Multinational Observational Cohort on Acute Heart Failure (MOCA) study. Int J Cardiol 2013. [Epub ahead of print]
86. Pascual-Figal DA, Bonaque JC, Redondo B, et al. Red blood cell distribution width predicts long-Term outcome regardless of anaemia status in acute heart failure patients. Eur J Heart Fail 2009 ;11(9):840-6
87. Van Kimmenade RR, Mohammed AA, Uthamalingam S, et al. Red blood cell distribution width and 1-year mortality in acute heart failure. Eur J Heart Fail 2010 ;12(2):129-36
88. Pascual-Figal DA, Hurtado-Martinez JA, Redondo B, et al. Hyperuricaemia and long-Term outcome after hospital discharge in acute heart failure patients. Eur J Heart Fail 2007 ;9(5):518-24 (Pubitemid 46561480)
89. Novack V, Pencina M, Zahger D, et al. Routine laboratory results and thirty day and one-year mortality risk following hospitalization with acute decompensated heart failure. PLoS One 2010;5(8):e12184
90. Malek F, Ostadal P, Parenica J, et al. Uric acid, allopurinol therapy, and mortality in patients with acute heart failure-results of the Acute HEart FAilure Database registry. J Crit Care 2012 ;27(6):737 ; e11-24
91. Park HS, Kim H, Sohn JH, et al. Combination of uric acid and NTProBNP: A more useful prognostic marker for short-Term clinical outcomes in patients with acute heart failure. Korean J Intern Med 2010 ;25(3):253-9
92. Cengel A, Turkoglu S, Turfan M, Boyaci B. Serum uric acid levels as a predictor of in-hospital death in patients hospitalized for decompensated heart failure. Acta Cardiol 2005 ;60(5):489-92 (Pubitemid 41433654)
93. Alimonda AL, Nunez J, Nunez E, et al. Hyperuricemia in acute heart failure. More than a simple spectator? Eur J Intern Med 2009 ;20(1):74-9
94. Mebazaa A, Gayat E, Lassus J, et al. Association between elevated blood glucose and outcome in acute heart failure: Results from an international observational cohort. J Am Coll Cardiol 2013 ;61(8):820-9
95. Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, Vasan RS. Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond. Stat Med 2008 ;27(2):157-72 (Pubitemid 351193639)
96. Abraham WT, Fonarow GC, Albert NM, et al. Predictors of in-hospital mortality in patients hospitalized for heart failure: Insights from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). J Am Coll Cardiol 2008 ;52(5):347-56 (Pubitemid 352005813)
97. Peterson PN, Rumsfeld JS, Liang L, et al. A validated risk score for in-hospital mortality in patients with heart failure from the American Heart Association get with the guidelines program. Circ Cardiovasc Qual Outcomes 2010 ;3(1):25-32
98. Lee DS, Austin PC, Rouleau JL, et al. Predicting mortality among patients hospitalized for heart failure: Derivation and validation of a clinical model. JAMA 2003 ;290(19):2581-7 (Pubitemid 37443288)
99. Felker GM, Leimberger JD, Califf RM, et al. Risk stratification after hospitalization for decompensated heart failure. J Card Fail 2004 ;10(6):460-6
100. Jong P, Vowinckel E, Liu PP, et al. Prognosis and determinants of survival in patients newly hospitalized for heart failure: A population-based study. Arch Intern Med 2002 ;162(15):1689-94
101. Au AG, McAlister FA, Bakal JA, et al. Predicting the risk of unplanned readmission or death within 30 days of discharge after a heart failure hospitalization. Am Heart J 2012 ;164(3):365-72
102. Ross JS, Mulvey GK, Stauffer B, et al. Statistical models and patient predictors of readmission for heart failure: A systematic review. Arch Intern Med 2008 ;168(13):1371-86 (Pubitemid 352008418)
103. Kansagara D, Englander H, Salanitro A, et al. Risk prediction models for hospital readmission: A systematic review. JAMA 2011 ;306(15):1688-98
104. Brophy JM, Deslauriers G, Rouleau JL. Long-Term prognosis of patients presenting to the emergency room with decompensated congestive heart failure. Can J Cardiol 1994 ;10(5):543-7